BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16813883)

  • 1. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
    Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
    J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.
    Moul JW; Maygarden SJ; Ware JL; Mohler JL; Maher PD; Schenkman NS; Ho CK
    J Urol; 1996 Mar; 155(3):982-5. PubMed ID: 8583622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells.
    Bass R; Perry B; Langenstroer P; Thrasher JB; Dennis KL; Tawfik O; Holzbeierlein J
    J Urol; 2009 Feb; 181(2):615-9; discussion 619-20. PubMed ID: 19091346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
    Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma.
    Takeda H; Akakura K; Masai M; Akimoto S; Yatani R; Shimazaki J
    Cancer; 1996 Mar; 77(5):934-40. PubMed ID: 8608487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are positive surgical margins in radical prostatectomy specimens an independent prognostic marker?
    Saether T; Sørlien LT; Viset T; Lydersen S; Angelsen A
    Scand J Urol Nephrol; 2008; 42(6):514-21. PubMed ID: 18752153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
    Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
    Williams MD; Roberts D; Blumenschein GR; Temam S; Kies MS; Rosenthal DI; Weber RS; El-Naggar AK
    Am J Surg Pathol; 2007 Nov; 31(11):1645-52. PubMed ID: 18059220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
    Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis.
    Lee CM; Lee RJ; Hammond E; Tsodikov A; Dodson M; Zempolich K; Gaffney DK
    Gynecol Oncol; 2004 Apr; 93(1):209-14. PubMed ID: 15047238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
    J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer.
    Sanderson KM; Penson DF; Cai J; Groshen S; Stein JP; Lieskovsky G; Skinner DG
    J Urol; 2006 Nov; 176(5):2025-31; discussion 2031-2. PubMed ID: 17070244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.